TWD 47.5
(-1.04%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 99.35 Million TWD | -8.53% |
2022 | 106.5 Million TWD | 49.35% |
2021 | 71.31 Million TWD | -17.85% |
2020 | 86.8 Million TWD | -23.21% |
2019 | 113.04 Million TWD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 51.26 Million TWD | 70.33% |
2024 Q2 | 34.67 Million TWD | -32.36% |
2023 Q4 | 30.09 Million TWD | 24.02% |
2023 FY | - TWD | -8.53% |
2023 Q3 | 24.26 Million TWD | 4.6% |
2023 Q2 | 23.2 Million TWD | 301.47% |
2023 Q1 | 5.77 Million TWD | -54.32% |
2022 FY | - TWD | 49.35% |
2022 Q4 | 12.65 Million TWD | 0.0% |
2021 FY | - TWD | -17.85% |
2020 FY | - TWD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Allied Biotech Corporation | 204.79 Million TWD | 51.487% |
GeneFerm Biotechnology Co., Ltd. | 231.09 Million TWD | 57.009% |
Easywell Biomedicals, Inc. | -85.5 Million TWD | 216.197% |
TTY Biopharm Company Limited | 1.52 Billion TWD | 93.483% |
Synmosa Biopharma Corporation | 1 Billion TWD | 90.151% |
Orient EuroPharma Co., Ltd. | 582.93 Million TWD | 82.957% |
Center Laboratories, Inc. | -175.17 Million TWD | 156.716% |
Tien Liang BioTech Co., Ltd. | 31.04 Million TWD | -219.988% |
Orient Pharma Co., Ltd. | 172.39 Million TWD | 42.371% |
InnoPharmax Inc. | -62.12 Million TWD | 259.932% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 126.67 Million TWD | 21.573% |
Excelsior Biopharma Inc. | -29.36 Million TWD | 438.282% |
DV Biomed Co., Ltd. | 407.64 Million TWD | 75.628% |
Foresee Pharmaceuticals Co., Ltd. | -912.16 Million TWD | 110.892% |
Handa Pharmaceuticals, Inc. | 802.78 Million TWD | 87.624% |
UniPharma Co., Ltd. | -16.25 Million TWD | 711.234% |
Anxo Pharmaceutical Co., Ltd. | 131.31 Million TWD | 24.339% |
Alar Pharmaceuticals Inc. | 394.52 Million TWD | 74.817% |
Winston Medical Supply Co., Ltd. | 228.32 Million TWD | 56.487% |
Mercury Biopharmaceutical Corporation | -39.03 Million TWD | 354.522% |
Bioray Biotech Co., Ltd | 12.13 Million TWD | -718.706% |